The Alzheimer’s Disease International conference opens today in Lyon. WDC trustees and members are here — joining researchers, advocates, and care professionals from around the world at one of the most important moments in dementia in years. #ADI2026
The first disease-modifying treatments for Alzheimer’s disease are here. For too many patients, they remain out of reach. Five international advocacy leaders on the gap — and the work ahead. bit.ly/4t06dNF
Payer decisions on Alzheimer’s treatments aren’t purely technical. They are political. And politics responds to pressure. A Policy Dispatch from WDC Executive Director Lenny Shallcross on access, anger, and what the dementia field needs to find. bit.ly/4rZhhJO
Event reminder Tomorrow Fionna Carragher hosts a WDC virtual dialogue on blood-based biomarkers in clinical practice — joined by Professor Vanessa Raymont, Jeff Burns and Mark McLelland. Learn more: bit.ly/4sFS0p9
Our March update is now published in @alzdemjournals.bsky.social. Ageing populations, effective treatments, and persistent access gaps — the update examines the two interconnected challenges that will define dementia policy for decades to come. bit.ly/3NBUWE1
On Thursday Fionna Carragher is joined by Professor Vanessa Raymont, Jeff Burns, and Mark McLelland for a WDC virtual dialogue on blood-based biomarkers moving into clinical practice. One of the most consequential questions in dementia right now. Learn more: bit.ly/4sFS0p9
Brain health is having its moment. But does that help or hinder the case for funding Alzheimer’s research and treatment? A new WDC transcript brings together advocates, scientists, and clinicians to work through the question. bit.ly/4bCMnSA
From equity gaps in clinical research to the promise of finger-prick testing — a new WDC transcript captures what world-leading biomarker scientists said about where the field is heading and what still needs to be solved. bit.ly/4t7yv8x
Regulators approved treatments that slow Alzheimer's progression. Payers across Europe said no. And the dementia community has largely accepted it. A new Policy Dispatch from WDC Executive Director Lenny Shallcross asks: where has all the anger gone? bit.ly/4rZhhJO
Reminder: The science of Alzheimer’s biomarkers is advancing — but implementation in health systems lags behind. On 9 April, Dr Fiona Carragher chairs a WDC dialogue on bridging that gap. Learn more: bit.ly/4diGBGM
In case you missed it: Regulators have approved disease-modifying treatments for Alzheimer’s in Europe — yet payers are not following suit. On 7 April, @hilaryevansnewton.bsky.social chairs a WDC discussion on what advocates can do. Learn more: bit.ly/4seP96q
With #ADPD2026 drawing to a close, the discussions throughout the week have highlighted meaningful progress in treatments, diagnostics and prevention. We leave encouraged by the work shared in Copenhagen and the partnerships supporting progress across the dementia field.
In case you missed it at #ADPD2026: WDC member Phyllis Ferrell chaired the symposium “Blood Biomarkers: A Completed Chapter or Work in Progress? Practical Challenges and Solutions for Real‑World Implementation,” focused on advancing real‑world use of BBMs in Alzheimer’s disease.
In case you missed it at #ADPD2026: WDC trustee Philip Scheltens chaired the symposium “Insights Into the EVOKE and EVOKE+ Trials of Semaglutide in Early Alzheimer’s Disease,” opening the session and presenting new clinical and biomarker results.
In case you missed it, earlier today at #ADPD2026: Miia Kivipelto chaired the symposium “Continue Life Their Way: Early Intervention in Alzheimer’s Disease,” examining the value of early and continued management of early Alzheimer’s disease. WDC member Frank Jessen also presented during the session.
Starting soon at #ADPD2026: WDC trustee Philip Scheltens chairs the fireside debate “Industry Meets Academia: Moonshots and Milestones.” He’ll join the discussion on the future of neurodegeneration drug discovery, alongside WDC member Niranjan Bose.
Following along from @leatgrinberg.bsky.social's #ADPD2026 plenary — a reminder that even as powerful new biomarkers emerge, studying brain tissue directly remains essential for grounding new discoveries in what the biology actually shows.
Day 1 #ADPD2026 is now under way. Earlier today Miia Kivipelto chaired “Prevention and Resilience in Dementia and Aging” symposium, where she also presented new findings from World‑Wide FINGERS. WDC Trustee, Philip Scheltens also presented on primary prevention of Alzheimer’s.
We’re glad to be in Copenhagen as #ADPD2026 begins. Our executive director, Lenny Shallcross, is attending, and we’re looking forward to new findings across treatments, diagnostics and prevention. Follow along this week as we highlight the work and presentations of our members and trustees.
Plasma biomarkers could transform Alzheimer's diagnosis — but only if health systems choose to adopt them. On 9 April, Dr Fiona Carragher chairs a WDC dialogue on moving biomarkers from research into real-world practice. Learn more: bit.ly/4diGBGM
Disease-modifying treatments for Alzheimer's are approved in Europe — but patients still can't access them. On 7 April, @hilaryevansnewton.bsky.social chairs a WDC discussion on advocacy, access, and what comes next. Learn more: bit.ly/4seP96q
The rise of “brain health” is opening doors with policymakers, but it also raises questions. This month’s WDC update in @alzdemjournals.bsky.social captures global perspectives on how the framing can reach new audiences while keeping the needs of dementia at the centre: bit.ly/40dSOVz
People aged 50–79 will soon outnumber children worldwide, concentrating much of the global risk of dementia. World Dementia Council executive director Lenny Shallcross looks at what an ageing population means for brain health 🧠, prevention and access to treatment: bit.ly/4ugCWiQ
📰 ICYMI: February’s @alzdemjournals.bsky.social features our 2026 programme — from brain health and advocacy to AI and technology, plus summits in Istanbul, London and Guangzhou — focused on moving dementia science into better care. Learn more: bit.ly/4qaA9EP
Registration is now open for the WDC Satellite Summit in Istanbul on 29 April 2026. Held the day before the @alzassociation.bsky.social AAIC Satellite Symposium, this invitation-only meeting will convene global leaders to advance brain health worldwide. Learn more: bit.ly/4o8Sd1j
📰 In the latest edition of @alzdemjournals.bsky.social, the World Dementia Council previews its 2026 programme: brain health and advocacy, AI and technology, and summits in Istanbul, London and Guangzhou to turn dementia science into better care. Read more: bit.ly/4qaA9EP
What role does advocacy play in shaping global dementia policy? Our next virtual dialogue — part of the WDC advocacy series — will tackle this question and more. 👉 Learn more: bit.ly/48JXQx4
The World Dementia Council is pleased to be a Brain Economy Action Forum Pathfinder organisation supporting “The Human Advantage: Stronger Brains in the Age of AI,” a new report from the McKinsey Health Institute and World Economic Forum. Learn more: bit.ly/4qrTUsh
Dementia is not just a medical challenge — it’s a global one. Ageing populations demand urgent action on research, care and innovation. The WDC is driving collaboration to keep dementia high on the global agenda. More: bit.ly/49ObAap
We were proud to attend the World Brain Health Forum 2026. Hosted by @institutducerveau.bsky.social it was an inspiring gathering of global leaders advancing brain health and dementia innovation. Collaboration is key to progress on diagnostics, treatments, and risk reduction.#WBHF2026